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Background and Significance 
Over half of all hospitalized patients are treated with 
antibiotics and antibiotic use is rising. There has been a 500% 
increase in antibiotic associated diarrhea, a common side effect 
of antibiotic use, in the last decade. Probiotics are a safe and 




The majority of patients admitted to the medical intensive 
care unit receive antibiotic therapy; however, few are 
prescribed probiotic therapy concurrent with antibiotics. 
 
Project Design 
Education was provided to health care providers regarding 
antibiotic associated diarrhea and the benefits of probiotic 
use. A guideline was developed to assist health care providers 
in ordering probiotics. 
 
Evaluation Plan 
Health care providers’ knowledge, attitude, and beliefs, 
pre and post education intervention were evaluated. Probiotic 
prescribing rates were tracked pre and post intervention. 
 
Results 
  There was a statistically significant increase in knowledge 
and a significant change in attitude after the education 
intervention. There was also a 2 fold increase in prescribing 




Attempt this practice change on a unit with a more stable 
staff and a non ICU population. Potentially use yogurt instead 
of a probiotic tablet in the practice guideline. Also, 
soliciting change champions may promote probiotic use.  Using a 
flag in the medication ordering system to remind providers to 
order a probiotic or yogurt concurrently with antibiotic therapy 
may also increase probiotic prescription rates. Additional 
research at the institution is recommended to demonstrate the 
effectiveness of probiotics. 
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Introduction 
Antibiotic use for hospitalized patients continues to 
increase, as do the complications, costs, and morbidities from 
diarrhea associated with antibiotics. Probiotics have been shown 
to prevent or reduce the incidence of diarrhea associated with 
antibiotics. This project investigated the effect of an 
education session and prescription guideline on the knowledge, 
attitudes, and beliefs of physicians and nurses regarding 
probiotics, as well as on rates of prescribing a probiotic 
concurrently with antibiotic therapy pre and post intervention. 
Background and Significance 
 Over half of all hospitalized patients are treated with 
antibiotics, which accounts for 20-50% of all hospital drug 
costs (Pestotnik, Classen, Evans, & Burke, 1996). Even though 
there is concern about bacterial resistance, antibiotic use at 
United States hospitals is rising (Dunham, 2008). At a group of 
United States academic medical centers, antibiotic use rose 7 
percent from 2002 to 2006 (Pakyz, MacDougall, Oinonen, & Polk, 
2008). Antibiotic associated diarrhea (AAD) is a frequent side 
effect of antibiotic use. In the last decade, there has been a 
500% increase in cases of AAD (Meier, 2005).  
 The clinical presentation of AAD ranges from mild to 
severe. Pseudo membranous Clostridium difficile (C. difficile) 
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is a toxin-induced colitis and the most severe manifestation of 
AAD (Meier, 2005). In up to 70-80% of diarrhea cases, the cause 
of the diarrhea is not specific, and in 20% it is due to C. 
difficile (Hurley & Nguyen, 2002). In hospitalized patients, AAD 
has been associated with increases in mortality, length of stay, 
and cost of medical care (Brossard & Surawicz, 2004).   
 One of the major mechanisms for the development of AAD is 
related to an alteration in the intestinal flora. The intestine 
is one of the largest bacterial reservoirs in humans (Gill & 
Guarner, 2004). The organisms present in the intestine are 
delicately balanced to benefit both the organism and the host. A 
multitude of factors can disrupt this balance including food, 
drugs, general health, and alteration of the types and numbers 
of bacteria present (Gill & Guarner). One of the most 
significant causes of disturbance of the gastrointestinal flora 
is antibiotic therapy (Sellin, 2001). The normal anaerobic gut 
microflora metabolizes high-molecular-weight carbohydrates into 
absorbable short-chain fatty acids. When the gut microflora is 
altered by antibiotics, high-molecular-weight carbohydrates 
accumulate in the colon and cause osmotic diarrhea (Reisinger, 
Fritzsche, Drause & Drejs, 2005). Antibiotics that can reduce 
the number of gut anaerobes are aminopenicillins, 
cephalosporins, and clindamycin (Doron, et al., 2008); however, 
almost every antibiotic has the potential to cause AAD and C. 
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difficile, including the antibiotics used to treat C. difficile 
(Hurley & Nguyen, 2002).  
 Disturbances of the gut microflora also promote the 
overgrowth of distinct pathogenic bacteria. About 16-20% of AAD 
cases are caused by C. difficile (Chassany, Michaux & Bergmann, 
2000, Reisinger et al., 2005, Sellin, 2001). The triggering 
event for C. difficile diarrhea is disruption of the normal 
colonic microflora, usually caused by a broad-spectrum 
antibiotic (Hurley & Nguyeun, 2002). After the disruption of the 
colonic microflora, colonization of C. difficile occurs by 
ingestion of heat-resistant spores that convert to vegetative 
forms in the colon. The effect of an antibiotic on the 
intestinal system depends on the antibacterial spectrum and the 
concentration in the intestinal lumen (Chassany et al., 2000). 
Moreover, antibiotics with the broadest spectrums like 
penicillins, cephalosporins, and clindamycin, and those with a 
high intraluminal concentration in the intestinal tract lead to 
greater changes in the normal flora of the intestines (Chassany 
et al.). The more profound the alteration of intestinal flora by 
a given antibiotic, the more likely it is to cause AAD (Doron, 
Hibberd & Gorbach. 2008). Bile acids, which escape absorption in 
the small bowel, are usually deconjugated and dehydroxylated by 
bacteria. When the bacterial flora is disturbed, unmetabolized 
dehydroxy bile acids, which are potent secretory agents, lead to 
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development of secretory diarrhea in the colon (Reisinger et 
al., 2005). 
 Some antibiotics, such as erythromycin, display a molecular 
design similar to that of the paracrine peptide motilin, which 
induces intestinal motility. Thus, erythromycin may bind to and 
stimulate the motilin receptors, stimulating transit in the 
intestine, with resulting increase in intestinal contractility 
(Sellin, 2001). Clavulanate also stimulates small bowel 
motility.  
 Other contributing risk factors for the development of AAD 
are prolonged use of antibacterial therapy, repeated antibiotic 
therapy, and the combination of antibiotics. The highest 
incidence of AAD in hospitals is in the intensive care unit 
(Bergogne-Berezin, 2000). Additional risk factors for AAD 
include: patient immune status and age, route of antibiotic 
administration, and inpatient/outpatient status (Boyle, Robins-
Browne, & Tang, 2006). It has been proposed that patients less 
than six years of age or greater than 65 years of age, with a 
past history of AAD, with severe underlying diseases, with 
chronic disease of the GI system, immunosuppression, GI surgery, 
or who are receiving antibiotics via nasogastric tube have 
increased risk of AAD (Bergogne-Berezin).  
The rate of C. difficile acquisition is estimated to be 13% 
in patients with hospital stays of up to two weeks and 50% in 
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those patients with hospital stays longer than four weeks 
(Schroeder, 2005), meaning that patients could experience this 
complication well after hospital discharge. C. difficile 
diarrhea can occur up to eight weeks after discontinuation of 
antibiotics (Hurley & Nguyen, 2002). The cost of treating C 
difficile infections is $2000-$4000 per hospital stay (Broussard 
& Surawics, 2004;Hickson, 2007). 
Significance of Probiotics 
 Probiotics are defined as live microorganisms that, when 
administered in adequate amounts, confer a beneficial effect on 
the health of the host (FAO/WHO, 2001). Probiotics modulate 
mucosal and systemic immunity, as well as improve nutritional 
and microbial balance in the intestinal tract (Penner, Fedorak, 
& Madsen, 2005). Probiotics are known to: colonize the 
intestinal tract, repopulate the gut with nonpathogenic flora, 
enhance immune responses, and inhibit or even kill pathogenic 
bacteria (Doron, et al., 2008).  
 Probiotics are lactic acid producing cultures that 
stimulate colonization of the human original flora in a 
beneficial direction (Cedgard, 1998). A microorganism must 
exhibit certain criteria to be a probiotic. It must be of human 
origin, safe in nature, unaffected by gastric acid and bile, 
adhere to intestinal mucosa, and be able to produce 
antimicrobial substances, modulate immune responses, and 
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influence human metabolic activities (Hanaway, 2006). Probiotic 
dosages are expressed in billions or millions of organisms, for 
example 10
10 
cfu (colony forming units). Probiotics exhibit 
strain-specific differences in their resistance to acid and 
bile, ability to colonize the gastrointestinal tract, clinical 
efficacy, and benefits to the health of the host (Pham, Lemberg 
& Day, 2008). Bifidobacteria and lactobacilli are commonly used 
as probiotics (Gill & Guarner, 2004). Lactobacillus rhamnosus GG 
(LGG) and Saccharomyces boulardii have the most level 1 evidence 
to support use in preventing antibiotic associated diarrhea 
(Pham, et al.). Probiotics are a safe, cost effective measure to 
prevent or reduce AAD (Hickson, et al., 2007).  
Safety of Probiotics 
 The safety of LGG has been evaluated more than any other 
probiotic (Snydam, 2008). In the United States, most probiotics 
have the status of generally recognized as safe (GRAS), 
therefore probiotics are not subject to specific standards 
(Vanderhoff & Young, 2008). However, LGG has been rigorously 
studied in academic institutions. These studies have validated 
the effectiveness of LGG with AAD (Vanderhoff & Young). LGG has 
shown to be safely used in many human populations including 
pregnant women, premature neonates, the elderly, children with 
diarrhea from rotovirus, hospitalized children and adults with 
diarrhea, malnourished children, patients with rheumatoid 
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arthritis, adults with Crohn’s disease, adults with Helicobacter 
pylori infection, and adults with C. difficile diarrhea 
(Snydman). There have been rare cases of bacteremia and liver 
abscess in patients with short gut syndrome (Snydam). All 
probiotics should be used with caution in patients who: are 
immune compromised, have short bowel syndrome, central venous 
catheters, elderly patients, and those with cardiac valve 
disease (Syndam). In the institution where the practice change 
was undertaken, patients are considered immune compromised if 
they are: receiving chemotherapy for cancer, have bone marrow 
suppression, are hemodynamically unstable beyond a few days or 
have multiple organ failure, have received an organ transplant, 
have a significant history of alcohol abuse or have a white 
blood cell count of <4000 or absolute polymorphonuclear 
leukocyte <1000 (H. Dedhia, personal communication, April 15, 
2009). Since probiotics are viable organisms, it is feasible 
that the host could become infected by them.  However historical 
data shows that lactobacilli in either food or capsule form are 
safe for human use (Reid, 2003). 
It is estimated that there are more than 20 billion doses 
of probiotics taken in a year and only a few reports of 
bacteremia (Reid, 2005). In a retrospective study by Salminen, 
et al. (2004), there were 89 cases of lactobacilli bacteremia, 
of which 11 might have been related to probiotic LGG use. In 82% 
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of these cases, patients had severe or fatal comorbidities. In 
Finland, the annual per capita consumption of LGG increased from 
1 liter to 6 liters between 1995 and 2000. Researchers in 
Finland studied all Lactobacillus blood isolates from 1990-2000 
and found that the rate of Lactobacillus bacteremia remained 
constant over time (Ouwehand, Saxelin, & Salminen, 2004 & 
Salminen, et al.). Even though probiotic use appears to carry a 
very low risk, Doron, et al. (2008) recommends that healthcare 
providers change gloves and wash hands after handling LGG and 
before manipulating vascular catheters. 
Probiotic Dose 
 According to the World Gastroenterology Organization (2008) 
and Hickson, et al. (2007), the recommended dose of LGG for 




 cfu, BID. This dose was 
based on evidence from well-designed and properly powered 
clinical trials. 
Problem Statement 
 A large majority of patients admitted to the medical 
intensive care unit at the selected trauma center receive 
antibiotic therapy, with many receiving multiple antibiotics 
concurrently, putting them at high risk for AAD. However, few 
patients are prescribed probiotic therapy concurrent with the 
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antibiotic treatment, an intervention that might significantly 
reduce the risk of AAD. 
Theoretical Framework 
 Two theories guided this capstone project, one serving as a 
framework for the patient intervention, and the other a 
framework for the provider intervention. 
Homeostasis Theory 
 Claude Bernard’s Homeostasis Theory framed the patient 
intervention. In the mid 1800’s Bernard described the importance 
of the concept of the constant internal environment. Bernard 
believed that life is an expression of the physical reality and 
the maintenance of life is guaranteed by the constancy of the 
fluid matrix or milieux interieur (Bernard. 1927). Cannon coined 
the term homeostasis to describe the constancy of the internal 
variable and the regulatory integrated mechanisms directed to 
preserve it (Cannon, 1929). Homeostasis does not mean the 
environment is immobile or stagnate, but rather that conditions 
vary, but remain relatively constant (Cannon). Shortly after 
birth, humans become colonized with microbes that are dynamic 
components of the body (CAST, 2007). Intestinal microbes are 
fairly stable through the life span, but can be impacted by 
antibiotics (CAST). Homeostasis is about the condition of an 
optimal internal environment for cell and tissue function at any 
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moment in time. Health occurs when bodily function is able to 
provide the appropriate environment (McVicar & Clancy, 1998). 
Failure to provide an optimal internal environment will cause 
further destabilization, and the integration of physiological 
functioning will become impaired. A change in the activities of 
one system may have far-reaching consequences for whole body 
function (McVicar & Clancy). 
The human gastrointestinal tract is home to over 400 
microorganisms. Most of this indigenous flora exhibit health 
promoting properties, but some can cause disease. Usually there 
is a balance between the good and bad bacteria. However, the use 
of antibiotics is known to exert a significant influence on the 
number and species of microorganism that inhabit the gut (Gill & 
Guarner, 2004). Probiotics can help restore the body’s normal 
intestinal flora and the internal environment, thereby 
maintaining homeostasis and decrease the risk for AAD and C.-
difficle, as they occur due to a disruption in the homeostasis 
of the GI tract. 
Change Theory 
 Lewin’s Change Theory (Lewin, 1997) was used to guide the 
practice change. Lewin’s theory consists of three essential 
stages:  unfreezing, moving to a new level or changing, and 
refreezing. Unfreezing involves a method of making it possible 
for health care providers to change their behavior. To 
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facilitate unfreezing education was provided to both physicians 
and nurses. 
When thoughts, perceptions, feelings, and attitudes move to 
a new level, a change has occurred. A guideline was provided to 
assist physicians in the process of ordering probiotics. 
Additionally, the project director participated in daily rounds 
for the first two weeks of the project. 
Refreezing is establishing the change as a new habit. This 
would occur when it becomes the standard of practice to order 
probiotics with certain antibiotics. If refreezing does not 
occur, the old behavior returns (Schein, 1995). This would mean 
that probiotics would not be ordered. 
 According to Schein (1995), Lewin’s concept of unfreezing 
emphasizes the observation that the stability of human behavior 
is based on “quasi-stationary equilibria” supported by a large 
force field. Lewin assumes that in any situation there are both 
driving and restraining forces that influence any change that 
may occur. These forces can be positive, influencing one toward 
a behavior, or negative, pushing one away from a behavior.  
Driving forces are those forces affecting a situation that are 
pushing in a particular direction. Driving forces tend to 
initiate a change and keep it going. However, restraining forces 
are forces acting to restrain or decrease the driving forces 
(Schein). 
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 For this project unfreezing activities included the 
education program which contained information regarding 
antibiotic associated diarrhea and the benefit of probiotic use. 
Additionally an evidence-based guideline was developed. The 
education was presented to the physicians who order probiotics 
and to the bedside nurse, who could facilitate the ordering of 
the probiotic. During the moving phase, the project director 
maintained close contact by participating in rounds with the 
physicians in the MICU. This allowed for questions to be 
answered and encouragement to be given for the practice change. 
The evidence-based practice guideline was in place to assist new 
residents who rotate through the unit as well as other 
physicians. Driving forces included: encouragement from the 
project facilitator, pressure from the staff physicians, 
reminders from the bedside nurse, and enthusiasm or “buy in” 
generated from the educational program. Restraining forces 
included health care providers that doubt the benefit of 
probiotics and hence do not order them. Theoretically, in the 
refreezing phase, physicians in the MICU would be consistently 
ordering probiotics for patients receiving antibiotic therapy 
and nurses would support this practice. The effectiveness of the 
change was monitored by comparing prescribing rates per and post 
guideline introduction and education. 
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Project Description 
Literature Review 
In order to identify potential practice protocols, a 
thorough literature search was conducted. Data bases searched 
included the National Guidelines Clearinghouse, the Cochrane 
Library, Pub Med, and CINAHL from 1999 to present. Search terms 
were probiotics, antibiotics, adults, and diarrhea in various 
combinations. The National Guidelines Clearinghouse yielded one 
guideline but it was not specific to probiotics and diarrhea.  
The Cochrane Library yielded three hits: two were protocols not 
yet developed and one was a review on probiotics for the 
prevention of pediatric antibiotic–associated diarrhea. Pub Med 
initially yielded 2201 hits, with probiotic as the search term. 
Adding diarrhea narrowed the search down to 545, which was 
further narrowed to 40 by adding antibiotics and adult. An 
exhaustive review was completed on this search and 7 articles 
were retrieved for this paper. Through the use of snowballing 
the article from the WHO organization was obtained.  
Seven articles will be reviewed, three randomized control 
trials, one systematic review, and three meta-analyses. All of 
the studies address the use of probiotics with AAD and were 
published from 2002-2007. 
 The focus of a study by Cremonini, Di Caro, Nista, 
Bartolozzi, Capelli, G. Gasbarrini, et al. (2002) was to perform 
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a meta-analysis of published trials on the efficacy of 
probiotics in reducing the incidence of AAD. Inclusion criteria 
were: only placebo-controlled trials, diarrhea as the primary 
end-point, and only studies with a minimum of two week follow-
up. Data regarding diarrhea was based on presence or absence of 
diarrhea; results based on differences in the amount of daily 
stool were excluded from analysis. Only seven placebo-controlled 
trials matched the inclusion criteria. The trials included used 
Lactobacillus spp. or Saccharomyces boulardii a single probiotic 
species instead of a combination of probiotics. A total number 
of 881 patients were studied in the trials, with an age range of 
two weeks to elderly. Of the seven trials reviewed, three 
identified a decrease in the occurrence of AAD during 
administration of Saccharomyces boulardii and four during the 
administration of Lactobacillus spp. The results of this study 
showed an overall reduction in the risk of AAD during probiotic 
administration in the studies considered. It was further noted 
that even though data suggests a positive role for probiotics in 
AAD, lack of standardization of probiotic preparations may 
impact research findings. The author calls for more equivalent 
probiotic formulations. 
 D’Souza, Rajkimar, Cooke and Bulpitt (2002) performed 
another meta-analysis to evaluate the efficacy of probiotics in 
prevention and treatment of diarrhea associated with the use of 
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antibiotics. All randomized, double blind trials that compared 
the effects of probiotic therapy and placebo were included. The 
percentage of patients without diarrhea in the probiotic and 
placebo groups was used as the outcome measure. Nine trials were 
included in the final analysis. All trials studied the efficacy 
of a probiotic in the prevention of AAD. The studies used 
probiotics combined with one or more antibiotics. The numbers of 
patients and duration of follow-up varied greatly from study to 
study, but the patients’ characteristics were similar in both 
treatment and placebo group. The combined odds ratios were 
similar between the yeast trials (Saccharomyces boulardii) and 
the non yeast trials; both favored active treatment over placebo 
in the prevention of AAD. The odds ratio for pooled data from 
all nine trials was in favor of probiotics over placebo in the 
prevention of AAD 0.37 (0.26 to 0.53; P<0.001). Six studies 
showed a significant benefit of probiotic treatment compared 
with placebo. This meta-analysis concluded that probiotics may 
be useful in preventing AAD, but it provided little support for 
treating AAD already in existence. Moreover, it indicated that 
probiotics are increasing in availability, have a low cost, and 
lack side effects in contrast to the problems associated with 
antibiotics. 
In a randomized trial, Beniwal, Arena, Thomas, Narla, 
Imperiale, Chaudhry, et al. (2003) studied the effectiveness of 
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a dietary supplement of yogurt for the prevention of AAD. Two 
hundred two hospitalized adult patients receiving oral or 
intravenous antibiotics were randomized to receive or not to 
receive a dietary yogurt supplement. The yogurt contained 10
6
 
cultures of L. acidophilus, L. bulgaricus, and S. thermophilus 
combined. The intervention group received yogurt twice daily for 
eight days within 12 hours of starting an antibiotic. Within 
each block, six subjects were randomized to one of two groups to 
ensure a balance in the number of subjects assigned to receive 
yogurt or no treatment. Randomization was stratified according 
to whether patients were receiving C. difficile treating 
antibiotics, metronidazole or vancomycin, or non C. difficile 
treating antibiotics. Treatment assignment was not revealed to 
the patient until they agreed to enroll in the study. Yogurt 
decreased the risk of developing AAD by nearly 50% (p=0.04).  
The total number of diarrheal days was 60 in the control group 
and 23 in the yogurt group. The incidence of AAD in the control 
was 23.7% which is consistent with other reports of frequency of 
AAD. The incidence of AAD in the yogurt group was 12.4%.  Based 
on the results, the absolute risk reduction implies that nine 
patients (95% confidence interval 4.1-132.6) need to be treated 
with yogurt to prevent one case of AAD. The study was not 
double-blinded due to the nature of the intervention. However, 
patient responses were elicited in a standardized fashion by 
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certified dieticians, which may have mitigated the effect of the 
lack of blinding. Incorporating a treatment arm consisting of 
yogurt without active cultures would have strengthened the 
study. It is also noted that the results are based on the 
combination of specific probiotics; therefore, the results 
cannot be applied to single probiotics or other dosages or 
combinations. This study demonstrated that during the course of 
antibiotic therapy, supplementation with commercially available 
yogurt that contains active cultures is a simple, safe, and 
cost-effective method of reducing the occurrence and severity of 
AAD. 
 Hawrelak, Whitten, and Myers (2005) performed a systematic 
review to determine if co-administration of LGG with antibiotics 
reduced the subsequent incidence of AAD. A systematic review was 
done on six, placebo controlled trials that compared the effects 
of a probiotic and a placebo on AAD. Statistical heterogeneity 
of the trials did not allow meta-analysis. The heterogeneity of 
the systematic review was found to be due to one study; without 
the one study, the trial results were all statistically 
homogenous. Four of the six trials found a significant reduction 
in the risk of AAD with co-administration of LGG. One of the 
trials reduced the number of days with AAD and the final trial 
found no benefit. All patients in the four positive trials 
received oral antibiotics and were outpatients. The participants 
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in the negative study were inpatients and an unspecified number 
of patients received IV antibiotics. There were a total of 638 
participants, ages two weeks to 93 years. Daily doses of LGG 
ranged from 1 x 10
10
 to 4 x 10
10
. Duration of treatment days 
ranged from 7-14 days. Limitations of this systematic review 
include a small number of studies that examined the use of LGG 
and AAD. Some of the studies had a small number of participants. 
Additionally different antibiotics were used, as well as 
different dosages of LGG. LGG is the probiotic to be 
administered in this project and most of the studies showed a 
decrease in the percentage of subjects with diarrhea: 5% vs 16%, 
8% vs 26%, 29% vs 30%, 3% vs 27% and 5% vs 30%. 
 McFarland (2006) performed a meta-analysis to compare the 
efficacy of probiotics for the prevention of AAD and the 
treatment of C. difficile disease (CDD) based on published 
randomized, controlled clinical trial. Twenty-five randomized 
controlled trials, with a sum total of 2,810 patients, provided 
data regarding efficacy of probiotics. The types of probiotics 
varied from single strains to mixtures of probiotics. Daily 
doses ranged from 1 x 10
7
 to 1 x 10
11
.  Use of a high dose (> = 
10
10
/day) of probiotic was associated with more effectiveness 
with AAD. The duration of probiotic treatment also varied from 
five days to eight weeks. In this meta-analysis, three types of 
probiotics (Saccharomyces boulardii, LGG, and probiotic 
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mixtures) significantly reduced the development of AAD. Only 
Saccharomyces boulardii showed significant reductions in 
recurrences of CDD. Limitations of this study include the 
varying types of probiotics and antibiotics, varying doses, 
varying age of participants, and variations in sample size. 
Although there were limitations, the data synthesis from twenty-
five randomized controlled trials showed that probiotics 
significantly reduced the relative risk of AAD. From six of the 
randomized controlled trials the combined efficacy showed 
probiotics have a significant protective effect for CDD. 
 A randomized, double blind, placebo controlled trial by 
Hickson, D’Souza, Muthu, Rogers, Want, Rajdumar, et al. (2007) 
studied the efficacy of a probiotic drink containing 
lactobacillus for the prevention of diarrhea associated with 
antibiotic use and diarrhea caused by C. difficile. One hundred 
and thirty five hospitalized patients taking antibiotics were 
studied. The treatment group received a probiotic drink 
containing L casei imunitass, (1.0 x 10
8
 cfu/ml), S thermophilus 
(1.0 x 10
8
 cfu/ml), and L. bulgaricus (1.0 x 10
7
 cfu/ml).  The 
placebo group received a sterile milkshake. The treatment group 
and placebo group received the drink twice daily during 
antibiotic treatment and for one week after the antibiotic was 
completed. Twelve percent of the probiotic group developed AAD 
compared to 34% in the placebo group. This study concluded that 
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consumption of a probiotic drink containing L casei, L 
bulgaricus, and S thermophilus can reduce the incidence of AAD. 
The study could not establish which bacteria species was 
effective. It is possible that the bacteria work 
synergistically, or one species may be more effective than 
another. As a result, the results cannot be generalized to other 
probiotic products. 
 In the most recent placebo-controlled, double blind study 
by Koning, Jonkers, Stobberingh, Mulder, Rombouts, and 
Stockbrugger (2007), the effect of a multispecies probiotic on 
the composition and metabolic activity of intestinal microbiota 
and bowel habits was studied in healthy volunteers taking 
amoxicillin. Forty subjects were enrolled in the study, 19 in 
the probiotic group and 21 in the placebo group. Volunteers 
received 500 mg of amoxicillin twice daily from day 1-7 and were 
randomized to receive either 5 grams of a multispecies probiotic 
or 5 grams of a placebo twice daily from day 1-14. The probiotic 
contained 10 different bacterial species at each 10
8 
cfu/g, the 
total does being 10
9 
cfu/g (b. bifidum, B longum, E. faecium, L. 
acidophilus, l. paracasei, la. Plantarum, LGG, and l. 
salivarius. Congruent with other studies, the intake of a 
multispecies probiotic resulted in a decrease in diarrhea-like 
bowel movements. During the probiotic period, diarrhea was 
reported less frequently in the probiotic group (48%) than in 
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the placebo group (79%). The study used healthy adult volunteers 
who received the same oral antibiotic and either a multispecies 
probiotic or a placebo. 
Synthesis 
For the purpose of this literature review, three randomized 
controls, one systematic review, and three meta-analyses were 
examined. In all of the studies reviewed from 2002-2007, 
patients receiving a probiotic reported less frequent diarrhea. 
Cremonini, et al. (2002) showed an overall reduction in the risk 
of AAD during probiotic administration. D’Souza, et al. (2002) 
concluded that probiotics may be useful in preventing AAD, but 
provided little support for treating AAD. Beniwal, et al. (2003) 
showed that during the course of antibiotic therapy, 
supplementation with commercially available yogurt that contains 
active cultures is a simple, safe, and cost-effective method of 
reducing the occurrence and severity of AAD. Additionally, 
Hawrelak found that when LGG was administered, there was a 
decrease in the percentage of subjects with diarrhea. In 
McFarland’s meta-analysis, the data synthesis from twenty-five, 
randomized, controlled trials showed that probiotics 
significantly reduced the relative risk of AAD.  Hickson, et al. 
(2007) and Koning, et al. (2007) also showed a decrease in the 
incidence of developing AAD when the patient was given a 
probiotic.  
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Based on a review of the literature, there is sufficient 
evidence to support the practice of administering probiotics 
concurrently with antibiotics in high risk patient populations, 
after screening for potential contraindications. The proposed 
practice change project is supported by evidence found in the 
literature.  
Congruence of Organizations Strategic Plan 
 This project supports the mission, values, goals, and 
strategic plan of West Virginia University Hospital (WVUH). The 
mission of WVUH is to provide a quality healthcare system, 
including tertiary services, to the citizens of West Virginia 
and the surrounding region (WVUH, 2008). WVUH (2008) values 
patient, team, and community. The mission of WVUH is achieved 
through strategic planning with a focus on improving the health 
status of the local community and the state of West Virginia and 
maintaining a strong financial position (WVUH). This project was 
designed to  assist in achieving the mission by improving the 
health status of the patients in MICU. The use of probiotics can 
promote returning of the patients’ intestinal microflora to a 
pre-antibiotic state, thus potentially decreasing mortality and 
morbidity (Hickson, et al. 2007). Based upon the findings of a 
study by Hickson, et al., it is estimated that a decrease in 
patient length of stay might also occur.  
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Project Objectives 
 The main objective of the project was to introduce a 
guideline for ordering probiotics concurrently with antibiotics. 
An additional objective of the project was to increase knowledge 
of physicians and nurses regarding incidence and effect of AAD 
and the use of probiotics to reduce the risk for and length of 
AAD. Another objective was to achieve a 50% increase in 
prescribing rates of probiotics for patients receiving 
aminopenicillin, cephalosporin, and clindamycin type antibiotics 
in the medical intensive care unit at a Midatlantic academic 
hospital by July 2009. The probiotic was to be ordered 
concurrently with the antibiotic by the ordering physician. An 
additional objective was to impact physician and nurse attitudes 
about the safety and effectiveness of probiotic use by 
presenting an educational program about the benefit of probiotic 
use with antibiotics in patient care. The project was completed 
during the period of May-July 2009 (Appendix G). 
Project Design 
Evidenced Based Intervention Plan 
 A Curriculum for the Role of Probiotics in the Prevention 
of Antibiotic Associated Diarrhea was developed (Appendix A).  
Additionally, an evidence-based practice guideline for 
prescribing probiotics was developed to assist physicians and 
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nurses in ordering probiotics concurrently with identified 
antibiotics (Appendix E). A pretest/posttest was developed based 
on a review of the literature. The assessment test was reviewed 
for clarity and readability by ten nursing faculty at the School 
of Nursing prior to administering the test. 
The educational program about probiotics and AAD as well as 
the guideline for ordering probiotics was presented at a 
research rounds to physicians in the MICU. The nurses in the 
MICU were educated by through use of a poster presentation. An 
informational poster was placed in the break room in MICU 1, 
MICU 2, and SICU. Placing posters in all 3 units assured easy 
access to the nurses.  
  Prior to the education, a Probiotic Knowledge, Attitude, 
and Belief Assessment pretest was placed in the mailbox of all 
nurses in the MICU and SICU (Appendix F). In addition a letter 
explaining the project and thanking the nurses for their 
participation was placed in each mailbox. The education program 
was approved for continuing education credit; thus a contact 
hour was given to all nurses who completed the pretest and 
posttest. The pretests were collected throughout a 2 week period 
and then the posters were placed in each unit. The poster 
remained in the units for 6 weeks, with posttests being 
collected periodically throughout the 6 weeks. Certificates for 
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contact hours were given to all nurses who completed the 
posttest.  
The pretest/posttest is a quasi-experimental design as it 
measures change within groups. Additionally, prescribing rate of 
probiotics for six weeks prior to and six weeks post 
intervention and for 13 weeks after the project ended were 
obtained from a data analyst for the hospital. The number of 
patients admitted to the unit, the number of antibiotics 
prescribed, and the numbers of c difficile diagnoses were also 
collected. 
 Resources 
 The resources for the project included the time of the MICU 
director, Dr. Dedhia, and other MICU physicians, residents, 
bedside nurses, MICU nursing administrators, pharmacists, and 
dieticians. The room and equipment that is normally used for 
grand rounds was used for the educational program. The budget 
included a cost of $37.00 for preparing the posters. Education 
for physicians occurred during research rounds, a routine 
education time. The nurses’ education did not take nurses 
outside of the care setting, as it occurred via poster board 
format. Nurse champions were informally identified during the 
education process through expressed interest and enthusiasm for 
the project. This allowed for promotion of the project during 
times when the project director was not on the unit. Probiotics 
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are currently covered by insurance, thus there is generally no 
cost to the patient receiving them.  The cost of LGG is $0.14 
per dose (G. Gill, personal communication, September 22, 2008) 
and insurance is billed the minimum charge of $3.26 (G. Gill 
personal communication, September 24, 2008). 
Evidence of Key Site Support 
 Harakh V. Dedhia, MD, medical director of the medical 
intensive care unit was in support of the project (Appendix B). 
Dr. Dedhia is board certified in internal medicine, pulmonary 
disease, and critical care medicine, with a special interest in 
nutrition. Chris Frenecak, a registered dietitian for MICU, was 
also in support of the project (Appendix C). Mary Fanning, 
Nursing Administration Director, granted permission to complete 
the project in the MICU (Appendix D). 
Evaluation 
 The project was evaluated in two ways. The health care 
provider’s knowledge, attitudes, and beliefs toward probiotic 
use were evaluated and probiotic use was monitored. A pretest 
was given to the health care providers before the education 
program and a posttest followed the education program.  
Probiotic prescribing rates, MICU admissions, antibiotic 
prescribing rates, and C. difficile rates were obtained from the 
data analyst for six weeks prior to the education program and 
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for six weeks after the intervention, as well as for 13 weeks 
after the project ended.  
 A paired t-test was used to compare knowledge scores from 
the pretest and posttest data. Pre and post intervention 
prescribing rates were compared to determine if the goal of a 
50% increase was met. In addition antibiotic prescribing rates, 
MICU admissions, and C. difficile rates were also compared. 
Results 
Demographics 
 Seventy-one percent of the 45 participants completing the 
pretest were registered nurses, 16% were physicians, 11% were 
dieticians and 2% were respiratory therapists. Forty-two 
participants completed the posttest: 64% were registered nurses, 
18% were physicians and 11% were dietitians. 
 Average length of time in practice for all health care 
providers was 11.7 years. Physicians had an average of 16 years 
with a range of 1-35 years of practice. Years of experience for 
nurses ranged from 0-33 years, with an average of 9.34 years.  
Dietitians had an average of 21 years of experience, with a 
range of 12-35 years. One respiratory therapist completed the 
testing with 8 years of experience. 
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Pretest/Posttest Results 
The survey measured knowledge, attitude, and beliefs.  A 
change in knowledge from pretest to posttest was measured with a 
paired t test by computing total scores for knowledge on 25 
items. The paired t test indicated a significant increase in 
test scores after education, t (df = 44) = 7.192, p = .000. Mean 
knowledge scores increased from 11.1 (SD = 2.68) pretest to 18.2 
(SD = 6.22) posttest.  
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1. Probiotics have same benefit, 
regardless of stain 
73 85 
2. Probiotics have strain-specific 
differences 
67 80 
3. Probiotics are not of human origin 80 90 
4. Probiotics are affected by gastric 
acid and bile 
37 23 
5. Therapeutic dose of LGG 18 86 
6. Probiotics with most level 1 
supportive evidence 
13 74 
7. Major risk factor for development 
of AAD 
67 79 
9. Increase in AAD in the last decade 7 74 
10. Highest AAD population 87 100 
11. Rate of C. difficile acquisition 
in hospitalized patient 
24 76 
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 ________________________ 




12. True/false all antibiotics cause 
AAD 
80 83 
Name three classifications of 
antibiotics that reduce gut 
anaerobes. 
  
13. One 38 90 
14. Two 36 93 
15. Three 34 93 
Probiotics should be used with caution 
in patients who  
  
 16. Are immune compromised, 65 95 
 17. Are receiving multiple 
antibiotics, 
81 88 
 18. Have short bowel syndrome, 61 88 
 19. Have a central venous catheter, 12 78 
 20. Are elderly,  67 78 
 21. Have cardiac valve disease. 33 88 
Precaution when handling a probiotic   
 22. No precaution, 72 89 
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 ________________________ 










 24. Use sterile gloves,  100 95 
 25. Change clean gloves and wash 
hands before central catheter 
49 85 
________________________________________________________________ 
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 Some knowledge questions changed substantially from the 
pretest to the posttest. Only 18% correctly identified the 
therapeutic dose of LGG on the pretest, while 86% were able to 
identify the correct dose on the posttest. Similarly, only  
4.5 % correctly identified the rise in antibiotic use from 2002 
to 2006 on the pretest, whereas 79% answered correctly on the 
posttest. In addition, 7% correctly identified the increase in 
AAD over the last decade on the pretest, and 74% on the 
posttest.  Only 24% were able to identify the incidence of C. 
difficile acquisition on the pretest, whereas 76% were able to 
identify the incidence on posttest.  Around 30% of participants 
were able to name three classifications of antibiotics that 
reduced the number of gut anaerobes on the pretest, whereas over 
90% were able to name three classifications of antibiotics on 
the posttest. Lastly, the greatest knowledge change regarding 
caution in probiotic use was identification of caution in 
patients who have a central venous catheter. On the pretest 12% 
answered this item correctly, and on the posttest 78% answered 
correctly. 
Attitude change was measured by computing total score for 
items indicating the level of agreement/disagreement with 
statements about the prevalence and severity of AAD as a health 
problem and the usefulness, safety and effectiveness of 
probiotic use concurrently with antibiotics. Low scores 
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represented the most positive attitude. There was a significant 
difference in pre and post scores, t (df=41) = 2.86, p = .007. 
Mean attitude scores decreased from 12.3 to 10.6, indicating a 
more positive attitude toward the significance of AAD as a 
health issue and the potential benefit of probiotic use. After 
education, the reported likelihood of prescribing probiotics 
together with antibiotics also increased significantly, t (df= 
38) = 3.13, p = .003.Mean scores decreased from 2.7 to 2.0.from 
pretest to posttest.  
Only 19 (42%) participants had prescribed or recommended a 
probiotic and 25 (56%) had never prescribed or recommended a 
probiotic. Twenty-nine (64%) of participants have known people 
who have used probiotics and 16 (36%) did not know of anyone who 
used probiotics. Twenty-five (56%) had personally used 
probiotics either in food sources or supplements and 20 (44%) 
had not used a probiotic.  
Themes in the open response items for reservations about 
recommending or prescribing probiotics included not being well 
informed on probiotic use and not having seen probiotics used in 
practice.  Themes identified with the question, “What might 
encourage you to prescribe or recommend probiotics?” included: 
more evidence of benefits, more education, increased knowledge, 
visual reminders, and ease of administration. 
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Prescribing Rates 
 There were 148 patients admitted to MICU service 6 weeks 
prior to the education intervention, and of those patients, 96 
(66%) were prescribed antibiotics. Of the patients receiving 
antibiotics, 2 (2%) received the probiotic LGG. There were 138 
patients admitted to MICU service during the 6 week post 
education study period and of those, 82 (59%) were prescribed 
antibiotics. Of these patients, 4 (5%) were prescribed the 
probiotic LGG. There was a 2 fold increase in probiotic 
prescribing rates; however there were a very small number of 
probiotics prescribed in total. In the time frame post study 
period (June 25-August 31), there were an additional 2 patients 
prescribed the probiotic LGG. Hospital-wide, there were 106 
patients prescribed a probiotic from January 17- September 18, 
2009. The overall probiotic prescribing rate was low throughout 
the hospital during this time frame. Probiotics received via a 
food source such as yogurt could not be determined, as this data 
is not tracked through the medical record system. 
 One of the two patients that received a probiotic before 
the education session had a confirmed diagnosis of C. difficile. 
Two of the four patients that received a probiotic during the 
six week post education intervention study period had a 
confirmed diagnosis of C. difficile, and another had diarrhea 
identified in the medical record. The two patients that received 
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a probiotic during the post study period both had a confirmed 
diagnosis of C. difficile. Eleven patients listed under MICU 
services had documented C. difficile pre invention and 5 
patients had documented C. difficile post intervention. 
Discussion 
Limitations 
The purpose of this project was to initiate a practice 
change to increase probiotic use concurrent with antibiotic use 
in the MICU. Several issues may have impacted the effect of the 
practice change project. First, the project director was not 
present in the unit on a daily basis, to serve as a constant 
change agent. Even though the residents who were assigned to 
this patient population were provided education regarding the 
practice change, the residents in the unit change on a monthly 
basis. Thus, residents who prescribed antibiotics during the 
latter weeks of the post intervention period most likely had not 
attended the education intervention session. The staff 
physicians were also provided the education session; however the 
staff physician rotates weekly, and all staff MD’s do not attend 
the research conference at which the education session was 
provided. The physician education session could not be conducted 
during grand rounds, where staff physician attendance might have 
been higher, due to scheduling conflicts.  
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Another limitation was the low rate of nurse completion of 
the poster education session. Posters were available in multiple 
locations, to assure availability to all staff RNs, yet only 30 
nurses (25%) completed the pre and post test. Thus, a large 
number of RN’s may have been unaware of the proposed practice 
change on the unit. In addition, although the nurses on the unit 
can suggest and/or remind physician to order a probiotic, they 
cannot themselves prescribe a probiotic for a patient.  It was 
not possible to collect data on nurse prompting behaviors; thus 
the potential impact of these behaviors is not known.  
Another limitation that became apparent related to the 
different roles of the project director and the physician 
providers. The practice change was being proposed by a nurse 
practitioner to physicians in the MICU. Physicians may be 
reluctant to change practice based on a recommendation from a 
nurse practitioner.   
In addition, an unexpected event occurred during the 
education session that may have impacted physician attitudes and 
behaviors related to the prescribing of probiotics. A pharmacist 
who attended the physician education session verbalized strong 
lack of support for the practice change. It appeared that he may 
not have been aware of the literature documenting the positive 
effects of probiotic use concurrent with antibiotics, but, 
nevertheless, voiced his concerns about the proposed practice 
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change. His comments may have negatively influenced the 
attitudes and behaviors of the MDs and residents in attendance 
at the session. 
Finally, it may be that the MICU is not the best unit to 
initiate the practice change of prescribing probiotics 
concurrently with antibiotics. The MICU patient population may 
have a higher prevalence of conditions for which probiotics use 
would be contraindicated or cautioned, such as immunocompromise, 
cardiac valve disease, and short bowel syndrome.  
Conclusions and Recommendations  
 This project met the identified objectives to increase the 
knowledge of MICU physicians and nurses about the significance 
of AAD and the benefits of probiotics in reducing patient risk 
for this treatment complication, and to increase prescribing 
rates for probiotics concurrent with antibiotics in the MICU 
patient population. However, the impact on achieving the mission 
and strategic plan of the University Hospital was minimal at 
best, because the probiotic prescribing rate, while increased, 
remained very low.  
As a result of this practice change project, several 
recommendations can be made for further interventions to promote 
the behavior of prescription of probiotics as adjuncts to 
antibiotic prescriptions. First, it might be best to attempt 
this practice change on a unit with both stable staff and stable 
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prescribers. Then, education would be most likely to affect a 
change in practice. A second recommendation would be to 
implement the practice change on a unit with a non ICU 
population, where there would be less contraindications or 
cautions for use with the patient population.  
An additional recommendation might be to use a yogurt 
containing LGG as an option for implementation of the probiotic, 
as physicians may be more willing to suggest yogurt for their 
patients than to prescribe a tablet that comes from the 
pharmacy. Use of yogurt might be perceived as “safer” than 
prescription of a formulary probiotic. 
 An additional recommendation would be to solicit 
champions from medicine, nursing, pharmacy, and dietary to 
promote the use of probiotics concurrently with antibiotic 
therapy. When there are champions in each area, the staff in 
those areas are more likely to participate in the practice 
change. 
 The use of a prompt or flag within the medication 
ordering system to remind providers to order a probiotic when 
ordering an antibiotic would, most likely, have a more 
significant impact on physician prescribing behavior. However, 
this change would require hospital-wide change in 
policy/procedure, and so would be a longer-term intervention.  
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Finally, conducting research at the institution that may 
demonstrate the effectiveness of probiotics in preventing and/or 
treating diarrhea resulting from antibiotic therapy might 
increase credibility of this behavior and result in increased 
“buy in” by physicians. It would be possible to continue to 
collect data related to C. difficile rates, the cost of diarrhea 
and C. difficile in terms of hospitalization, and probiotic 
prescription rates. Perhaps as providers recognize more fully 
the effect of preventing even one case of C. difficile, they may 
be more amenable to taking the additional steps of prescribing a 
probiotic along with the antibiotics that are prescribed. 
Summary and Implications 
 The education session did increase both physician and nurse 
knowledge of probiotics, and positively impacted their attitudes 
toward the use of probiotics in preventing AAD. In addition, the 
rate of probiotic prescription increased two-fold in the post-
education period, even though the prescription rate remained 
quite low. There were several intervening or hindering 
variables, which may have prevented a further change in attitude 
toward probiotics and probiotic prescribing rates. Given these 
intervening or hindering influences, several recommendations for 
future work in this practice change are suggested. 
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Attainment of Leadership Goals 
This project has contributed to my personal leadership 
goals in numerous ways. After coming up with a question, I was 
able to perform a literature review and systematically review 
research articles on the topic of probiotics and antibiotic 
associated diarrhea. I then incorporated two theories to guide 
the practice change. The practice change was designed to improve 
patient outcomes by applying research. I participated 
interprofessionally with physicians and nurses in the MICU to 
increase knowledge, change attitudes and beliefs, and increase 
prescribing rates of probiotics concurrently with antibiotics. I 
developed, implemented, and evaluated a practice change. I hope 
to continue to participate in promoting the use of probiotics 
concurrently with antibiotic therapy to prevent or decrease AAD 
in other areas of health care. 
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Appendix A 
Curriculum Outline 
The Role of Probiotics in the Prevention of Antibiotic 
Associated Diarrhea 
1.  What are probiotics? 
2.  The history of probiotics 
a.  Myths 
3.  Antibiotic associated diarrhea 
a.  The role of probiotics 
b.  Literature review 
c.  Recommendations 
d.  Safety Issues 
4.  Practice Change 
a.  When to order probiotics  
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Appendix B 
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Appendix C 
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Appendix D 
    Probiotics      45 
Appendix E 
Guideline for Ordering a Probiotic 
 







How long have you been in practice?  ____________ 
For the following statements please answer according to the 














_____Antibiotic Associated Diarrhea (AAD) is a significant 
health problem. 
_____AAD can cause increased mortality, length of stay and cost 
of medical care for hospitalized patients. 
_____There is sufficient evidence to support the routine 
administration of a probiotic concurrently with an antibiotic to 
reduce the occurrence and severity of AAD. 
_____In most patients, probiotics are a simple, safe, cost 
effective method of decreasing the occurrence and severity of 
AAD. 
_____I do not think probiotics are effective in reducing or 
preventing AAD. 
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The following questions are designed to assess knowledge about 
probiotics and their use with antibiotics. Please answer to the 
best of your ability. If you do not know the answer, please 
indicate that you do not know rather than leaving the question 
blank. Please circle the correct answer or fill in the blank.  
Thank you for completing this questionnaire. 
1.  Which statements about probiotics are true? 
a. Probiotics exhibit the same benefits, regardless of 
strain. 
b. Probiotics exhibit strain-specific differences. 
c. Probiotics are not of human origin. 
d. Probiotics are affected by gastric acid and bile. 
e. Unable to answer 
2.  The therapeutic dose of lactobacillus rhamnosus GG (LGG) is: 
a. Once a day 1010 colony forming units 
b. TID 1010 colony forming units 
c. BID 1010 colony forming units 
d. QID 1010 colony forming units 
e. Unable to answer 
3.  What probiotics have the most level 1 supportive evidence 
(evidence derived from at least one properly designed randomized 
controlled trial)? 
a. S. thermophilus and L. bulgaricus 
b. Saccharomyces boulardii and lactobacillus GG 
c. S. thermophilus and lactobacillus GG 
d. lactobacillus GG and L. bulgaricus 
e. Unable to answer 
4.  Have you ever prescribed or recommended a probiotic to a 
patient (either from a food source or an OTC supplement)? 
  Yes No 
5.  If you answered “no” to #4, do you have specific 
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6.  Have you known people who have used probiotics effectively 
(either from a food source or supplement)? 
  Yes No 
7.  Have you personally used probiotics either in food sources 
or supplements? 
  Yes  No 




9.  What is the major patient risk factor for the development of 
AAD? 
a. Poor general health 
b. Poor nutrition 
c. Age 
d. Alteration in intestinal flora 
e.Unable to answer 






e.Unable to answer 
11.  In the last decade there has been a ______________% 
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12.  The highest incidence of AAD is in: 
a. The outpatient population 
b. The intensive care unit 
c. The pediatric population 
d. The general medical unit 
e. Unable to answer 
13.  What is the incidence of clostridium difficile acquisition 
among hospitalized patients? 
a. 13% in patients with hospital stays of up to two weeks 
and 50% in those patient with hospital stay of up to 
four weeks 
b. 30% of all patients admitted to the hospital 
c. 7% in patients with hospital stays of up to two weeks 
and 20% in those patient with hospital stay of up to 
four weeks 
d. 25% in patients with hospital stays of up to two weeks 
and 50% in those patient with hospital stay of up to 
four weeks 
e. Unable to answer 
14.  All antibiotics have the potential of causing AAD. 
True False 
15.  Name three types of antibiotics that can reduce the number 
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16.  Probiotics should be used with caution in patients who 
have/are:  (check all that apply) 
_____immune compromised 
_____receiving multiply antibiotics 
_____short bowel syndrome 
_____central venous catheter 
_____elderly 
_____cardiac valve disease 
17.  How likely are you to prescribe or recommend a probiotic 
concurrently with an antibiotic? 
_____Very likely 
_____Somewhat likely  
_____Neither likely nor unlikely 
_____Somewhat unlikely   
_____Unlikely  









  Evaluation   
April, 2009   June   October, 2009   
 
 
  May/June, 2009   
September, 
2009 
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